Skip to main content
Explore URMC


Multiple Myeloma: A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Research Question:
How safe is and what is the tolerability of denosumab in newly diagnosed or relapsed multiple myeloma patients?

Basic Study Information

If you decide to participate in this study you will receive denosumab every 4 weeks for a total of 12 cycles.

Location: Cancer Center
Study Web URL:
Study Reference #: UMMY17073

Lead Researcher (Principal Investigator)

Lead Researcher: Brea Lipe

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405

Additional Study Details

Learn More About These Conditions

More information about Multiple Myeloma

Return to Search